Washington University School of Medicine led a study evaluating long-term gantenerumab treatment in individuals with dominantly inherited Alzheimer’s disease (DIAD). Gantenerumab was associated with serious safety concerns, including a high incidence of brain bleeding and swelling, possibly leading to an early study termination.
This article was originally published on MedicalXpress.com
What Are Boundaries? As the word portrays, boundaries in a relationship help each person establish expectations with their partner. Boundaries can help you communicate what you are comfortable with and what you are willing to […]
For at least three decades, researchers have gathered evidence that chronic stress puts pressure on the body to constantly adjust itself to restore physiological stability. This process is known as allostatic load and it creates a cascade […]
Microneedling is a revolutionary skincare treatment that has gained popularity in recent years due to its numerous benefits, including reducing the appearance of scars, wrinkles, and acne, and promoting collagen production. Edmonton, the bustling capital […]
© 2025 SimplyWell.ca